Order Article Reprints

Rodriguez E, Pei G, Zhao Z, Kim ST, German A, Robinson P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers. 2021; 13(20):5178. https://doi.org/10.3390/cancers13205178

Rodriguez, Emma, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German, and Prema Robinson. 2021. "Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871" Cancers 13, no. 20: 5178. https://doi.org/10.3390/cancers13205178

Rodriguez, E., Pei, G., Zhao, Z., Kim, S. T., German, A., & Robinson, P. (2021). Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers, 13(20), 5178. https://doi.org/10.3390/cancers13205178